# Kura Oncology Spins Out Lilly-Backed Biotech with $50M for Next-Gen Diabetes Therapy

Kura Oncology has created a new spinout company focused on a next-generation diabetes treatment. The spinout launches with $50 million in fresh funding and is backed by Eli Lilly. The new company will take forward the therapy through development.

Kura Oncology, a clinical-stage biopharmaceutical company primarily focused on cancer treatments, established the spinout to advance the diabetes program. The $50 million in funding will support the initial development of the therapy. Lilly’s involvement provides both financial backing and strategic support.

The spinout structure allows Kura to separate its oncology pipeline from the metabolic disease program. This approach lets each entity focus on its specific therapeutic area and development needs.

**Context**

Diabetes affects hundreds of millions of people worldwide, and the market for new treatments remains large. Next-generation therapies aim to improve upon existing options by offering better blood sugar control, fewer side effects, or more convenient dosing. The involvement of a major pharmaceutical company like Lilly, which has a long history in diabetes care, signals continued interest in novel approaches to metabolic disease. For the biotech industry, this spinout model demonstrates how companies can efficiently allocate resources and attract targeted investment for promising programs outside their core focus.

Source: [original report](https://www.fiercebiotech.com/biotech/kura-creates-lilly-backed-spinout-take-forward-next-gen-diabetes-therapy)